< User:Ivan E. Wang(Difference between revisions)
|
|
| (34 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| - | '''Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase) complex with (''R''/''S'')-emixustat and palmitate'''
| + | [[Media:RPE65_with_emixustat.mp4|PLACEHOLDER] width="576" height="324"] |
| | + | [[/Media:RPE65_with_emixustat.mp4]] |
| | | | |
| - | <StructureSection load='4rsc' size='340' side='right' caption='Emixustat bound in the active site of RPE65' scene=''> | |
| | | | |
| - | Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of ''all-trans''-retinyl ester to ''11-cis''-retinol in the visual cycle. | |
| | | | |
| - | (PLACEHOLDER This is a default text for your page '''Ivan E. Wang/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
| + | [[Media:RPE65_with_emixustat.mp4|PLACEHOLDER]] |
| - | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.)
| + | |
| | | | |
| - | = Function = | |
| - | == Structural Features of RPE65 == | |
| | | | |
| - | | + | [[Media:RPE65_with_emixustat.mp4]] |
| - | == Enzymatic Catalyzed Reaction ==
| + | |
| - | | + | |
| - | | + | |
| - | = Protein-Ligand Interaction =
| + | |
| - | == Endogenous Ligand ==
| + | |
| - | | + | |
| - | == Exogenous Ligand ==
| + | |
| - | === (''R'')-Emixustat (ACU-4429) ===
| + | |
| - | | + | |
| - | (''R'')-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (''R'')-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E.
| + | |
| - | | + | |
| - | In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (''R'')-emixustat as a potential inhibitor of RPE65. Currently (''R'')-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (''R'')-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema.
| + | |
| - | | + | |
| - | <StructureSection load='4rry' size='340' side='left' caption='(''R'')-emixustat bound in the active site of RPE65' scene=''>
| + | |
| - | | + | |
| - | === (''S'')-Emixustat ===
| + | |
| - | | + | |
| - | <StructureSection load='4ryz' size='340' side='right' caption='(''S'')-emixustat bound in the active site of RPE65' scene=''>
| + | |
| - | | + | |
| - | == ''R/S'' Enantiomers Differences ==
| + | |
| - | | + | |
| - | = Disease Implications =
| + | |
| - | | + | |
| - | = Medical Relevance =
| + | |
| - | | + | |
| - | | + | |
| - | | + | |
| - | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
| + | |
| - | | + | |
| - | </StructureSection>
| + | |
| - | = References =
| + | |
| - | <references/>
| + | |
